European Journal of Heart Failure

Papers
(The H4-Index of European Journal of Heart Failure is 53. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
1675
Reply to ‘Morphine use in acute cardiogenic pulmonary oedema: is MIMO trial enough to change practice?’281
Striving for the ‘perfect’ definition of iron deficiency in heart failure156
Identifying reliable biomarkers for pulmonary congestion: Toward a close yet sustainable heart failure follow‐up154
Letter regarding the article ‘Employment of artificial intelligence for an unbiased evaluation regarding the recovery of right ventricular function after mitral valve transcatheter edge‐to‐edge repair141
Reply to the letter regarding the article ‘Are mechanical circulatory supports the forgotten aspect in the implementation of therapies for heart failure?’129
Adrenomedullin as a marker of hypoxia, not hypoperfusion. Letter regarding the article ‘Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients h129
Heart failure: age is no excuse for complacency118
Expanding the horizon of medication adherence strategies in acutely decompensated heart failure. Letter regarding the article ‘Medication adherence in patients with acutely decompensated heart failure110
Rationale and design of the ESC Heart Failure III Registry – Implementation and discovery105
Percutaneous repair of moderate‐to‐severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE‐HF2 trial103
Issue Information101
Left ventricular volume and maximal functional capacity in heart failure with preserved ejection fraction: Size matters101
Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial92
Cardiovascular magnetic resonance‐estimated pulmonary capillary wedge pressure, congestion markers, and effect of empagliflozin in patients with heart failure with reduced ejection fraction92
Salt repletion and diuretic response: The role of serum chloride. A post‐hoc analysis of the SALT‐HF trial on furosemide and hypertonic saline solution administration in ambulato81
Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials81
Are left ventricular ejection fraction phenotypes meaningful in acute heart failure?78
Issue Information71
Association between liver fibrosis, plasma volume status, and cardiovascular mortality: The Hiroshima Study on Glucose Metabolism and Cardiovascular Diseases70
Risk factors for the development of heart failure in patients with or without prior myocardial infarction69
Similarities and distinctions between acetazolamide and sodium–glucose cotransporter 2 inhibitors in patients with acute heart failure: Key insights into ADVOR and EMPULSE67
Abstract67
Tafamidis in patients with severe heart failure due to transthyretin amyloidosis cardiomyopathy: Improved long‐term survival67
Applying the ‘touch‐and‐go’ concept to mineralocorticoid receptor antagonists: A paradigm shift in routine heart failure management66
Issue Information65
Exercise catheterization in adults post‐Fontan with normal and abnormal haemodynamic criteria: Insights into normal Fontan physiology64
Incidence and predictors of weaning failure from veno‐arterial extracorporeal membrane oxygenation therapy in patients with cardiogenic shock64
Burst steroid therapy for acute heart failure: The CORTAHF randomized, open‐label, pilot trial63
Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON‐HF62
Abstract62
Decongestion strategies in patients presenting with acutely decompensated heart failure: A worldwide survey among physicians61
Determinants of submaximal exercise intolerance in patients with heart failure and preserved ejection fraction: Insights from the lactate threshold61
Clinical profiles and prognostic impact of residual intravascular and tissue congestion in acute heart failure61
Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant‐level pooled analysis from the DAPA‐HF and DELIVER trials60
Culture, ethnicity, and socio‐economic status as determinants of the management of patients with advanced heart failure who need palliative care: A clinical consensus statement from the Heart Failure 60
Time‐varying analyses of survival and outcomes in patients with HeartMate 3 left ventricular assist devices59
Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology59
Dissecting the heart failure phenotype through phenomics59
Corrigendum to ‘Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy’ [Eur J Heart Fail59
Atrial cardiomyopathy: From healthy atria to atrial failure. A clinical consensus statement of the Heart Failure Association of the ESC59
July 2023 at a glance: heart failure with preserved ejection fraction and comorbidities57
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial57
Issue Information57
The dangerous liaison between epicardial adipose tissue and heart failure with preserved ejection fraction57
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial57
Correction to “Use of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence a55
Issue Information55
Normal and excessive muscle sympathetic nerve activity in heart failure: implications for future trials of therapeutic autonomic modulation55
Letter regarding the article ‘Association between antecedent myocardial infarction and heart failure with preserved versus reduced ejection fraction’54
Cardiopulmonary functional capacity: another piece of the puzzle of sodium–glucose cotransporter 2 inhibition in heart failure?54
Finerenone according to insulin resistance in heart failure: Insights from the FINEARTS‐HF trial54
Reply to the letter regarding the article ‘Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care’54
0.080137968063354